Indivior Pharmaceuticals tops Q3 revenue estimates, net income hits record
INDV•Indivior Pharmaceuticals reported Q3 revenue of $356 million, up 13% year over year and above estimates of $329.35 million, and adjusted EPS of $1.32 versus estimates of $1.12. It forecast FY 2026 revenue of $1.295 billion to $1.365 billion and expects to close its merger with Supernus on November 2.
1. Quarterly results
Q3 revenue rose 13% year over year to $356 million, beating the $329.35 million consensus estimate. Adjusted EPS was $1.32, above the $1.12 estimate, while the company reported record net income and non-GAAP net income.
2. Revenue and profit drivers
SUBLOCADE revenue grew 24%, which the company attributed to higher dispense unit volume, favorable price and mix, and gross-to-net adjustments. It said reduced GAAP and non-GAAP operating expenses improved profitability, and strong cash generation contributed to financial strength.
3. 2026 outlook and merger
Indivior expects FY 2026 net revenue of $1.295 billion to $1.365 billion, including SUBLOCADE revenue of $1.01 billion to $1.05 billion. It forecast adjusted EBITDA of $700 million to $740 million and expects to close its merger with Supernus on November 2.
